Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1190369 | 1.00 | FUCA1 (0.53) | FUCA1MEN1TSHRKMT2AGAA | |
| SCHEMBL6197152 | 1.00 | FUCA1 (0.53) | FUCA1MEN1TSHRKMT2AGAA | |
| SCHEMBL2896845 | 0.85 | ACHE (0.56) | FUCA1MEN1TSHRKMT2AGAA | |
| SCHEMBL7225926 | 0.84 | FUCA1 (0.50) | FUCA1MEN1TSHRKMT2AGAA | |
| SCHEMBL14702321 | 0.84 | ALDH1A1 (0.53) | FUCA1MEN1TSHRKMT2AALDH1A1 | |
| SCHEMBL23580048 | 0.83 | FUCA1 (0.61) | FUCA1MEN1TSHRKMT2AGAA | |
| SCHEMBL16903463 | 0.83 | ALDH1A1 (0.59) | FUCA1MEN1TSHRKMT2AGAA | |
| SCHEMBL9053848 | 0.81 | FUCA1 (0.47) | FUCA1MEN1TSHRKMT2AGAA | |
| SCHEMBL9053845 | 0.81 | FUCA1 (0.47) | FUCA1MEN1TSHRKMT2AGAA | |
| SCHEMBL23580095 | 0.81 | NR1I2 (0.48) | FUCA1MEN1TSHRKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| CN-101917981-B | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP | 2012-11-14 | — | — | CN | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| CN-101917981-A | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP | 2010-12-15 | — | — | CN | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7713965-B2 | 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL SA (FR) | 2010-05-11 | — | — | US | disclosed |
| US-7713965-B2 | 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL SA (FR) | 2010-05-11 | — | — | US | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009106967-A1 | NOVEL 7-SUBSTITUTED DERIVATIVES OF 3-CARBOXY-OXADIAZINO-QUINOLONES, PREPARATION THEREOF AND USE THEREOF AS ANTI-BACTERIAL AGENTS | VETOQUINOL SA (FR) | 2009-09-03 | — | — | WO | disclosed |
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-7288541-B2 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288541-B2 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288541-B2 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | disclosed |
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| EP-1494663-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SmithKline Beecham Corporation (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003086385-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003086385-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | CTSK, CTSB, CTSS | FUCA1 2883/4885MEN1 3362/4885TSHR 4310/4885 |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | FUCA1 991/4885MEN1 2465/4885TSHR 2947/4885 |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | CTSK, CTSB, CTSD | FUCA1 1427/4885MEN1 3686/4885TSHR 2623/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | FUCA1 1073/4885MEN1 3499/4885TSHR 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.